Clearmind Medicine announces milestones in Phase I/IIa trial for CMND-100

Clearmind Medicine (CMND) announced three milestones in its FDA-approved Phase I/IIa clinical trial for CMND-100-the Company’s proprietary, non-hallucinogenic, MEAI-based oral therapy targeting Alcohol Use Disorder. These achievements include positive top-line results from the first cohort, unanimous approval from the independent Data and Safety Monitoring Board to continue Phase I/IIa clinical trial and the commencement of enrollment at another clinical site in Israel, propelling the multinational study toward potential accelerated patient recruitment. In an announcement on November 18, the Company reported compelling top-line data from the trial’s initial cohort of six participants Who were dosed across elite sites including Johns Hopkins University School of Medicine and Yale School of Medicine’s Department of Psychiatry. Building on this momentum, Clearmind’s independent DSMB conducted a meticulous, unblinded interim safety review on November 24. The board unanimously recommended that the clinical trial continue. Just one day later, on November 25, Clearmind activated enrollment at another clinical site in its international consortium: Tel Aviv Sourasky Medical Center, one of Israel’s leading medical centers. Under the leadership of Principal Investigator Prof. David Zeltser, Director of Internal Medicine and Deputy Director of R&D and Innovation, TASMC welcomed its first patient-marking seamless site initiation and injecting fresh velocity into recruitment efforts. This joins an elite lineup of active centers, including Yale School of Medicine, Johns Hopkins University School of Medicine, and Hadassah Medical Center, enabling diverse, high-quality data accrual to power the trial’s next phases.